Eyenovia announced it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for two additional patent applications. The allowed patents provide fundamental coverage on physiologic microdroplet ejection diameters and velocities, which enable gentle delivery of ophthalmic therapeutics to the eye at velocities that beat the eye’s blink reflex.
Once issued, the new patents will complement Eyenovia’s existing intellectual property portfolio and are expected to further strengthen the company’s position as a leader in micro-therapeutic ophthalmic delivery with a total of 8 issued US patents and 27 issued and allowed international patents, according to a company news release.
“We are pleased that the USPTO continues to recognize the novel features of our piezo-print technology that has the ability to gently and efficiently deliver micro-therapeutic solutions to the eye,” Sean Ianchulev, MD, Eyenovia’s Chief Executive Officer and Chief Medical Officer, said in the news release. “With an expanding global intellectual property portfolio, we look forward to advancing our late stage clinical assets for mydriasis, glaucoma and myopia into phase 3 development.”